rotigotine (neupro) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Rotigotine is an agonist at all 5 dopamine receptor subtypes (D1-D5) but binds to the D3 receptor with the highest affinity. It is also an antagonist at α-2-adrenergic receptors and an agonist at the 5HT1A receptors. Rotigotine also inhibits dopamine uptake and prolactin secretion. It is FDA approved for the treatment of Parkinson's disease, restless legs syndrome. Dopamine antagonists, such as antipsychotics or metoclopramide, may diminish the effectiveness of Rotigotine. Common adverse reactions include nausea, vomiting, somnolence, application site reactions, dizziness, anorexia, hyperhidrosis, insomnia and dyskinesia.   NCATS

Chemistry

  • SMILES: CCCN(CCC1=CC=CS1)[C@H]2CCC3=C(O)C=CC=C3C2
  • InChIKey: KFQYTPMOWPVWEJ-INIZCTEOSA-N
  • Mol. Mass: 315.473
  • ALogP: 4.27
  • ChEMBL Molecule:
    rotigotine  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$1.6940 - $2.8498

United States

$16.2057 - $22.8061
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-naphthalenol, 5,6,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)- | 2-(n-n-propyl-n-2-thienylethylamino)-5-hydroxytetralin | (+--)-5,6,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol | (6s)-6-(propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol | ent-rotigotine | leganto | n 0437 | n-0437 | n 0437, hydrochloride, (r)-isomer | n 0437, hydrochloride, (s)-isomer | n 0437, (-)-isomer | n 0437, (+-)-isomer | n 0437, (r)-isomer | n 0923 | n-0923 | n 0924 | n-0924 | neupro | rotigotine | rotigotine, (+--)- | rotigotine cds | spm 962 | spm-962 | (s)-(-)-rotigotine

Organizations (30)

Research & Development (30)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (36)

Approved Indications (3)


 

Depression

Parkinson Disease

Restless Legs Syndrome

Experimental Indications - Clinical Trial Phases 1-4 (35)


 

Alzheimer Disease (Phase 2)

Anxiety Disorders (Phase 4)

Apathy (Phase 3)

Aphasia (Phase 2)

Aphasia, Primary Progressive (Phase 2)

Brain Diseases (Phase 2)

Central Nervous System Diseases (Phase 2)

Communication Disorders (Phase 2)

Deficiency Diseases (Phase 2)

Delusions (Phase 4)

Dementia (Phase 2)

Drugs, Generic (Phase 1)

Fibromyalgia (Phase 2)

Frontotemporal Dementia (Phase 2)

Frontotemporal Lobar Degeneration (Phase 2)

Healthy Volunteers (Phase 1)

Hypokinesia (Phase 4)

Kidney Failure, Chronic (Phase 3)

Language Disorders (Phase 2)

Mental Disorders (Phase 2)

Metabolic Diseases (Phase 2)

Nervous System Diseases (Phase 2)

Neurobehavioral Manifestations (Phase 2)

Neurocognitive Disorders (Phase 2)

Neurodegenerative Diseases (Phase 2)

Neurologic Manifestations (Phase 2)

Pain (Phase 2)

Parkinson Disease ()

Perceptual Disorders (Phase 2)

Pick Disease of the Brain (Phase 2)

Proteostasis Deficiencies (Phase 2)

Restless Legs Syndrome ()

Speech Disorders (Phase 2)

Stroke (Phase 2)

TDP-43 Proteinopathies (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 88
  • # of Trial Organizations: 30

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue